vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
Village Farms International, Inc. is the larger business by last-quarter revenue ($12.2M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs -60.3%, a 80.2% gap on every dollar of revenue. On growth, Village Farms International, Inc. posted the faster year-over-year revenue change (31.5% vs -49.9%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
PLX vs VFF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $12.2M |
| Net Profit | $-5.5M | $2.4M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | — |
| Net Margin | -60.3% | 19.9% |
| Revenue YoY | -49.9% | 31.5% |
| Net Profit YoY | -184.8% | 128.2% |
| EPS (diluted) | $-0.06 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $12.2M | ||
| Q3 25 | $17.9M | $66.7M | ||
| Q2 25 | $15.7M | $59.9M | ||
| Q1 25 | $10.1M | $77.1M | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $18.0M | $54.9M | ||
| Q2 24 | $13.5M | $53.6M | ||
| Q1 24 | — | $78.1M |
| Q4 25 | $-5.5M | $2.4M | ||
| Q3 25 | $2.4M | $10.2M | ||
| Q2 25 | $164.0K | $26.5M | ||
| Q1 25 | $-3.6M | $-6.7M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | $-820.0K | ||
| Q2 24 | $-2.2M | $-23.5M | ||
| Q1 24 | — | $-2.9M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | 47.9% | ||
| Q2 25 | 62.5% | 37.3% | ||
| Q1 25 | 19.1% | 14.7% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | 24.8% | ||
| Q2 24 | 29.8% | 25.4% | ||
| Q1 24 | — | 19.9% |
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | 23.3% | ||
| Q2 25 | 7.5% | 20.8% | ||
| Q1 25 | -41.0% | -8.0% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | 3.8% | ||
| Q2 24 | -18.0% | -43.5% | ||
| Q1 24 | — | -3.0% |
| Q4 25 | -60.3% | 19.9% | ||
| Q3 25 | 13.2% | 15.3% | ||
| Q2 25 | 1.0% | 44.2% | ||
| Q1 25 | -35.8% | -8.7% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | -1.5% | ||
| Q2 24 | -16.4% | -43.9% | ||
| Q1 24 | — | -3.7% |
| Q4 25 | $-0.06 | $0.01 | ||
| Q3 25 | $0.03 | $0.08 | ||
| Q2 25 | $0.00 | $0.24 | ||
| Q1 25 | $-0.05 | $-0.06 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | $-0.01 | ||
| Q2 24 | $-0.03 | $-0.21 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $81.2M |
| Total DebtLower is stronger | — | $33.7M |
| Stockholders' EquityBook value | $48.2M | $299.9M |
| Total Assets | $82.3M | $423.1M |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $81.2M | ||
| Q3 25 | $13.6M | $82.6M | ||
| Q2 25 | $17.9M | $60.0M | ||
| Q1 25 | $19.5M | $15.1M | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | $28.7M | ||
| Q2 24 | $23.4M | $29.7M | ||
| Q1 24 | — | $26.7M |
| Q4 25 | — | $33.7M | ||
| Q3 25 | — | $34.6M | ||
| Q2 25 | — | $39.1M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $43.3M | ||
| Q2 24 | — | $44.4M | ||
| Q1 24 | — | $46.1M |
| Q4 25 | $48.2M | $299.9M | ||
| Q3 25 | $52.9M | $295.4M | ||
| Q2 25 | $49.9M | $284.3M | ||
| Q1 25 | $45.2M | $248.3M | ||
| Q4 24 | $43.2M | — | ||
| Q3 24 | $32.4M | $274.4M | ||
| Q2 24 | $28.6M | $275.2M | ||
| Q1 24 | — | $296.2M |
| Q4 25 | $82.3M | $423.1M | ||
| Q3 25 | $82.3M | $418.4M | ||
| Q2 25 | $78.5M | $403.7M | ||
| Q1 25 | $73.9M | $377.1M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $61.6M | $417.8M | ||
| Q2 24 | $91.5M | $425.4M | ||
| Q1 24 | — | $458.4M |
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | — |
| Free Cash FlowOCF − Capex | $1.6M | — |
| FCF MarginFCF / Revenue | 17.8% | — |
| Capex IntensityCapex / Revenue | 4.4% | 90.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-3.7M | $24.4M | ||
| Q2 25 | $-5.2M | — | ||
| Q1 25 | $-5.1M | $-6.4M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | $4.3M | ||
| Q2 24 | $-3.6M | $5.7M | ||
| Q1 24 | — | $-50.0K |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | $22.6M | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | $-8.9M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | $1.5M | ||
| Q2 24 | $-3.8M | $4.8M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | 33.9% | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | -11.6% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | 2.7% | ||
| Q2 24 | -28.1% | 9.0% | ||
| Q1 24 | — | -2.5% |
| Q4 25 | 4.4% | 90.8% | ||
| Q3 25 | 2.8% | 2.7% | ||
| Q2 25 | 2.8% | 4.6% | ||
| Q1 25 | 3.0% | 3.3% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | 5.1% | ||
| Q2 24 | 1.3% | 1.6% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 2.39× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
